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Observations made more than 30 years ago introduced the concept of preclinical autoimmunity, which is characterized by the presence of autoantibodies long before the appearance of disease symptoms, thereby fundamentally changing the way that autoimmune disease is understood. This concept, which created a clear separation in time and space between disease onset and clinical manifestations, is now well established in several autoimmune diseases, in particular rheumatoid arthritis (RA) 1, 2 , systemic lupus erythematosus (SLE) 3 and type 1 diabetes mellitus 4, 5 . The idea of preclinical autoimmunity has influenced mechanistic studies and has given rise to the emerging field of preventive immunotherapy to re-induce immune tolerance 6, 7 .
Immune dysregulation in patients with RA occurs many years before joint inflammation begins [8] [9] [10] and is easily detectable in seropositive patients by the presence of antibodies against selected autoantigens. The decisive initial insult is the loss of self-tolerance, a host-protective function guarded by the adaptive immune system. Accordingly, disease-associated genetic polymorphisms identify T cells as key drivers of immune abnormalities in RA 11, 12 . Aberrant proliferation, commitment to proinflammatory effector functions, providing help to autoreactive B cells and tissue invasive properties are all phenotypic traits shared by T cells in RA and other chronic inflammatory conditions. These traits impose substantial metabolic demands on T cells, and metabolic reprogramming could have hallmark status in explaining the convergence of phenotypic traits that ultimately result in autoimmune inflammation.
Emerging metabolic patterns in T cells from patients with RA contrast with those in chronically activated healthy T cells, fostering the hope that metabolic programmes delineated in patient-derived cells represent vulnerabilities that can be exploited therapeutically. The inflammatory milieu of the inflamed joint has attracted attention as a site of hypermetabolic activity and high energy needs; however, the molecular features that separate inflammation in rheumatoid joints from other similarly active tissue lesions have not yet emerged. Possible features include molecular signatures for chronically stimulated innate and adaptive immune cells and metabolic profiles derived from stromal components of the joint. Reversing metabolic phenotypes could provide strategies for modulating immune responses with the ultimate aim of reconstituting immune health and intercepting tolerance defects long before joint inflammation occurs.
Major challenges to an integrated view of immunometabolism in RA derive from the fact that the disease process stretches over decades, involves several stages and occurs in multiple tissue environments, including
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Abstract | One of the fundamental traits of immune cells in rheumatoid arthritis (RA) is their ability to proliferate, a property shared with the joint-resident cells that form the synovial pannus. The building of biomass imposes high demands for energy and biosynthetic precursors, implicating metabolic control as a basic disease mechanism. During preclinical RA, when autoreactive T cells expand and immunological tolerance is broken, the main sites of disease are the secondary lymphoid tissues. Naive CD4 + T cells from patients with RA have a distinct metabolic signature, characterized by dampened glycolysis, low ATP levels and enhanced shunting of glucose into the pentose phosphate pathway. Equipped with high levels of NADPH and depleted of intracellular reactive oxygen species, such T cells hyperproliferate and acquire proinflammatory effector functions. During clinical RA, immune cells coexist with stromal cells in the acidic milieu of the inflamed joint. This microenvironment is rich in metabolic intermediates that are released into the extracellular space to shape cell-cell communication and the functional activity of tissue-resident cells. Increasing awareness of how metabolites regulate signalling pathways, guide post-translational modifications and condition the tissue microenvironment will help to connect environmental factors with the pathogenic behaviour of T cells in RA.
Glycolysis
An oxygen-independent metabolic pathway that generates two molecules of pyruvate, ATP and NADH from every one molecule of glucose, supporting the tricarboxylic acid cycle and providing intermediates for the pentose phosphate pathway, glycosylation reactions and the synthesis of biomolecules (including serine, glycine, alanine and acetyl-CoA).
Tricarboxylic acid (TCA) cycle
(Also known as the Krebs cycle) A set of connected pathways in the mitochondrial matrix, which metabolize acetyl-CoA derived from glycolysis or fatty acid oxidation, producing NADH and FADH 2 for the electron transport chain and precursors for amino acid and fatty acid synthesis.
Electron transport chain
A series of proteins in the inner mitochondrial membrane that transfer electrons from one to the other in a series of redox reactions, resulting in the movement of protons out of the mitochondrial matrix and in the synthesis of ATP.
Oxidative phosphorylation
A metabolic pathway that produces ATP from the oxidation of acetyl-CoA and the transfer of electrons to the electron transport chain via NADH and FADH 2. lymphoid and non-lymphoid organ sites. Although information on immune cell conditioning by different tissue environments is still scant, studies of naive T cell populations not entrapped in the inflamed joints provide insights into primary immune responses and the early stages of RA. The joint lesion in the late stages of RA provides an opportunity to explore how cellular metabolism can condition the tissue milieu and how metabolites can 'moonlight' as intracellular and extracellular signalling molecules. In this Review, we examine emerging data on metabolism in immune cells in seropositive RA and look at how metabolic programmes affect the disease process, focusing on T cells as a key driver of tolerance breakdown.
T cell metabolism in early RA
The early steps of the disease process in RA occur in lymphoid organs, where lymphocytes are primed and differentiate into effector and memory cells. Subsequently, self-reactive T cells and B cells become perpetually activated and expand, releasing cytokines and autoantibodies. In some, but not all, individuals who reach this stage, another protective hurdle is broken; autoreactive T cells and B cells then invade the synovium, functioning as immunopathologic agents by forming organized lymphoid structures and eliciting defective repair mechanisms, supported by myeloid cells, endothelial cells, fibroblasts, chondrocytes and bone cells. Inflammation-induced neoangiogenesis provides easy access for immune cells into the synovial lesion 13, 14 . Although it is the most visible battleground, the joint is not the only tissue affected by RA. Throughout all stages of RA, secondary lymphoid tissues supply T cells and B cells to peripheral tissues. Eventually, the spectrum of nonlymphoid organs targeted during RA widens, creating extra-articular manifestations. In all these tissue environments, communication between lymphoid and nonlymphoid cells ultimately determines the activation state, longevity and functional behaviour of the cells involved, and subsequently the tissue damage that is clinically associated with RA. Thus, the pathologic process leading to RA stretches over decades and involves multiple, fundamentally different tissue microenvironments (FIG. 1) . Although more information is needed for a contextual analysis of the metabolic environment in lymphoid tissues, progress has been made in understanding intracellular metabolic conditions in naive T cells, thus shedding light on early events in RA pathogenesis.
Over the past two decades, a series of fundamental characteristics have emerged that distinguish T cells from patients with RA and those from age-matched healthy individuals (FIG. 2) . Notably, such characteristics extend beyond antigen specificity and include basic biological pathways that enable T cells to transition from protective to auto-aggressive modalities. Central to their role in adaptive immunity, T cells undergo profuse expansion and contraction 15, 16 . T cells are able to adapt to severely restrictive bioenergetic conditions 17 , as they continue to produce cytokines and proliferate as long as glucose remains available 18 . Creating large amounts of biomass imposes a high demand for energy and biosynthetic precursors [19] [20] [21] .
Metabolic control of T cell function. Like other proliferative cells, T cells in patients with RA utilize all possible energy sources (sugars, fats and proteins), but glucose remains their major life-sustaining nutrient 22 . Glucose acts as an electron donor. Electron acceptor molecules capture some of the energy released by the stepwise oxidation of glucose and convert it into energyrich ATP and NADH. One molecule of glucose is broken down into two molecules of pyruvate by the process of glycolysis, with a net gain of two molecules of ATP and two molecules of NADH. The glycolytic pathway is an ancient ATP-producing pathway that is extremely adaptable 23 ; under acute energy requirements, glycolytic enzymes can be regulated within minutes. The drawback of this quick regulation is the incomplete oxidation of glucose and the build-up of lactate, which acidifies the cellular and extracellular microenvironments. Under oxygen-rich conditions, pyruvate is transported into the mitochondria and converted into acetyl-CoA to enter the tricarboxylic acid (TCA) cycle 24, 25 . This eight-step cycle generates NADH, FADH 2 and GTP, which function as electron donors for the electron transport chain. During oxidative phosphorylation, protein complexes in the mitochondrial inner membrane transfer electrons, forming a transmembrane proton gradient and ultimately creating water. T cells, like all cells, harness the energy from this proton gradient to generate ATP, with oxidative phosphorylation yielding 15 times more energy from each molecule of glucose than anaerobic glycolysis 26 .
Glycolysis and the pentose phosphate pathway in T cells. Studies using naive CD4 + CD45RA + T cells from patients with RA have delivered surprising results. Although naive T cells from healthy individuals meet activation-imposed energy demands by upregulating the glycolytic enzyme 6-phosphofructo-2-kinase/ fructose-2,6-bisphosphatase 3 (PFKFB3), induction of this enzyme is reduced in T cells from patients with RA 27, 28 . Through its kinase activity, PFKFB3 produces large amounts of fructose-2,6-bisphosphate, which activates phosphofructokinase 1, a rate-limiting glycolytic enzyme. PFKFB3 thus determines the intensity of glycolytic flux and is considered a preferred pharmacologic 
Pentose phosphate pathway (PPP)
An anabolic metabolic pathway parallel to glycolysis that branches out from glycolysis with the conversion of glucose-6-phosphate to ribose 5-phosphate and generates the reducing equivalent NADPH, ribose-5-phosphate (used in the synthesis of nucleotides and nucleic acids) and erythrose-4-phosphosphate (used in the synthesis of amino acids).
target for inhibiting the growth of cancers 29 . PFKFB3 deficiency occurs at an early point in the life cycle of T cells in patients with RA and has profound metabolic and functional consequences (FIG. 3) . As a result, lactate production is reduced and ATP levels are lower in such cells than in T cells from healthy individuals 27, 28 , identifying glycolytic ATP production as a major energy source in CD4 + T cells. In addition to results from patients with RA in the USA 27, 28 , low ATP production by circulating CD4 + T cells was also seen in patients with RA in a Japanese cohort 30 , attesting to the pan-ethnicity of this feature of RA. A low ATP signature might help to identify naive T cells in secondary lymphoid tissues that are prone to autoreactivity. Moreover, T cells from patients with RA have an increased susceptibility to apoptosis and fail to upregulate autophagy as a compensatory pathway for energy generation 27, 31, 32 . Impaired glycolysis has profound implications for such T cells and their immediate neighbourhood, as low levels of pyruvate production reduces the amount of substrate available for oxidative phosphorylation and thus reduces the generation of reactive oxygen species (ROS). At the same time, low levels of lactate production keep the extracellular pH relatively high and reduced oxygen utilization counteracts hypoxia and its regulatory effects, meaning that these T cells might fail to adapt to tissue hypoxia.
If naive T cells from patients with RA reduce flux through the glycolytic pathway, what is the fate of glucose in these cells? Two side branches of glycolysis, which have a critical role in cellular homeostasis, exist: the hexosamine biosynthesis pathway and the pentose phosphate pathway (PPP). Using glucose, glutamine, acetyl-CoA and uridine, cells can form N-acetylglucosamine for protein O-glycosylation and N-glycosylation through the hexosamine biosynthesis pathway 33, 34 . Post-translational modification of proteins by the addition of a single residue of O-linked N-acetylglucosamine has been implicated in regulating the activation of T cells and B cells [35] [36] [37] . Whether the post-translational modification of key molecules by the addition of O-linked N-acetylglucosamine differs between T cells from patients with RA and T cells from healthy individuals is currently unknown.
The PPP enables cells to generate products that are crucial for T cell function, as they fuel biomass generation and thus enable T cell expansion. Glucose is converted to glucose-6-phosphate, which enters the PPP to supply the pentose sugars required for nucleotide and nucleic acid synthesis. Glucose-6-phosphate dehydrogenase (G6PD) is the rate-limiting enzyme of the PPP and is responsible for the generation of NADPH and ribulose-5-phosphate. NADPH is the cell's most abundant reductive molecule, which, by its electron donor function, holds an important position in regulating the cellular redox status and providing reductive elements for the production of biomolecules. Naive T cells from patients with RA can be distinguished from T cells from healthy individuals by their distinctive shunting of glucose into the PPP (FIG. 3) . Compared with T cells from healthy individuals, T cells from patients with RA have increased amounts of G6PD mRNA and protein, and double the level of G6PD enzymatic activity 28 . Consequently, glucose-6-phosphate is shunted into the PPP, generating high amounts of NADPH and reduced glutathione. NADPH is important in controlling lipid synthesis, but the effect of increased PPP utilization in T cells from patients with RA on lipid homeostasis is unknown. 
. Short-lived and highly reactive ROS act as secondary messengers, swiftly altering cellular signalling pathways 38, 39 . Basic cellular functions, such as proliferation, differentiation, migration and cell death are now considered to be under the control of ROS 40 . Only if the equilibrium with antioxidant defence systems is disrupted will ROS damage proteins, nucleic acids, lipids, membranes and organelles, eventually triggering cell death. Studies of purified naive T cells from patients with RA and agematched healthy individuals show that patient-derived T cells are hyperproliferative 27, 28 , a state inducible in cells from healthy individuals by ROS scavenging 28 . The under lying molecular defect is a shortening of the G2-M phase of the cell cycle. G2-M bypassing occurs when there is insufficient activation of the cell cycle kinase serine-protein kinase ATM, part of a redox-dependent signalling pathway 41 . T cells from patients with RA that have low levels of ATM commit to the type 1 helper T (T H 1) cell and T H 17 cell lineages, rather than differentiating into regulatory T (T reg ) cells
. In a cohort of patients with RA, the ratio of G6PD to PFKFB3 correlated with clinical disease activity (as measured by 28-joint disease activitiy score), indicating a clinically relevant outcome of diverting glucose into the PPP 28 . Implicating reductive stress, as opposed to oxidative stress, in conferring risk for autoimmune arthritis might be considered contrary to the prevailing dogma, but fits well with groundbreaking work by Holmdahl and colleagues 42, 43 . This research group identified neutrophil cytosolic factor 1 (NCF1) and its associated ROS production as major genetic elements in autoimmune arthritis 43 . Previous studies had identified Ncf1 as a protective gene in rat arthritis 44 . Subsequent work provided detailed mechanistic information on how ROS can suppress inflammatory responses. One of these mechanisms connected macrophage-generated ROS to the suppression of T cell reactivity and to reduced arthritis severity 45 . ROS inhibited pro-arthritogenic T cells by altering thiol groups on the T cell membrane (and possibly in relevant signalling molecules), effectively modulating T cell activation and expansion 46 . ROS deficiency seems to facilitate spontaneous autoimmunity by promoting a type I interferon signature 47 . Notably, sufficient availability of ROS was also required for the induction of T reg cells 48 , emphasizing the role of redox signalling in balancing proinflammatory and anti-inflammatory immune responses. Thus, redox signalling is critically involved in multiple aspects of T cell biology, with an emerging theme of ROS preventing inappropriate T cell activation 49, 50 . Besides activating ATM, ROS serve as secondary messengers in many signalling pathways, including networks that sense the energetic status of a cell and regulate metabolism, such as the mechanistic target of rapamycin (mTOR) and AMP-activated kinase (AMPK) pathways. Coincidentally, mTOR and AMPK also function as master regulators of T cell differentiation and cell fate decisions. As AMPK and mTOR monitor the availability of nutrients, they guide T cells into clonal expansion or reduction and into committed functional lineages and effector functions. By adjusting the activity of AMPK and mTOR, lymphocytes not only match energy supply with demand, but also make decisions about entry into the cell cycle and conversion from naive to memory and terminally differentiated effector cells.
AMPK acts as a redox sensor 51 , being activated by increased AMP:ATP ratios, which result in the switching on of catabolic pathways and the switching off of anabolic pathways. Redox conditions predict that patient-derived T cells would not have high levels of activated AMPK
. The downstream consequences of a lack of activated AMPK would be profound, as AMPK activation affects several basic cellular functions 52 , including glucose uptake, glycolytic flux, mitochondrial biogenesis, fatty acid oxidation, transcriptional activity and cell cycle control. Little is known about the status of AMPK activation in T cells, but ROS deficiency is predicted to paralyze this master integrator of metabolism, proliferation and differentiation. In line with this model, therapeutic AMPK activation reportedly suppresses experimental arthritis 53, 54 and methotrexatemediated activation of an AMPK-dependent pathway is implicated in protecting the vasculature against inflammation 55 . Protein synthesis, cell growth, survival and proliferation, as well as cell fate decisions in differentiating T cells, are under the control of mTOR. Together with AMPK, mTOR is a central communicator, integrating environmental signals with cellular function and differentiation. 
PPP
Aberrant mTOR activation is associated with cellular senescence, and the mTOR complex 1 inhibitor rapamycin has been investigated as a therapeutic agent to counteract chronic cellular stimulation. mTOR is one of the anchor molecules that interlinks nutrient availability, energy generation and utilization, mitochondrial activity and T cell differentiation. Energy deprivation (as indicated by AMPK activation) and the suppression of mTOR activity are supposed to drive T cells to differentiate into T reg cells 19, 56 . However, the precise contribution of different components of the mTOR pathway is not entirely understood, and somewhat contradictory findings regarding the role of mTOR in T cell biology have fuelled discussions within the scientific community 57 . The ability of mTOR to integrate the regulation of nutrient supply, bioenergetics and T cell differentiation makes it a promising target for therapeutic intervention to suppress abnormal T cell differentiation during the early stages of RA [58] [59] [60] [61] .
A common factor of the crosstalk between extra cellular and intracellular cues seems to be ROS, which swiftly adapt cellular functions to the immediate tissue environment and the needs of the host. The reliance of T cells on ROS-dependent signals is likely to be particularly important in microenvironments with low levels of ROS, such as well-oxygenized secondary lymphoid organs. In the arthritic joint, ROS are abundant and participate in the feed-forward amplification of tissue damage 62 . Although ROS are needed to prevent emerging autoimmunity, ROS scavenging might be beneficial in lowering the inflammatory burden in the arthritic synovium. The multiple functions of ROS represent excellent opportunities to target different stages of RA therapeutically.
Immunometabolism in late RA
In the later stages of RA, the disease process migrates from the secondary lymphoid tissues to peripheral tissue environments, in particular the synovial lining of Glycolytic breakdown of glucose in T cells in rheumatoid arthritis is reduced as a result of diminished activity of the regulatory enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphophastase 3 (PFKFB3), which curbs ATP production. With increased activity of glucose-6-phosphate dehydrogenase (G6PD), glucose is shunted to the pentose phosphate pathway (PPP), yielding high amounts of the electron donor NADPH and generating biosynthetic precursors. Cellular stores of glutathione are shifted towards the reduced form, cellular levels of reactive oxygen species (ROS) are depleted and cellular oxidant signalling is impaired. ETC, electron transport chain; GLUT1, glucose transporter type 1; TCA, tricarboxylic acid. diarthrodial joints. Here, T cells, B cells and plasma cells, together with specialized antigen-presenting cells, create organized lymphoid structures 63, 64 and interact with tissue-resident cells such as fibroblast-like synoviocytes (FLSs), endothelial cells, macrophages, neuronal cells, chondrocytes and bone cells 65 . The synovial pannus has tissue-destructive and invasive properties 66, 67 , with features of a non-healing tissue wound. Fundamental biologic processes of the synovial pannus such as sustained proliferative signalling, angiogenesis, cellular de-differentiation and unbalanced bone turnover are associated with high metabolic demands in all cell types involved. Overall, the inflamed joint in patients with RA is a hypermetabolic lesion.
Hypermetabolic activity of immune and stromal cells creates a tissue environment that in itself can regulate cellular behaviour. Tissue-infiltrating immune cells, specifically T cells in the joints of patients with RA, should encounter chronic stimulatory conditions, which in turn should lead to exhaustion and cellular senescence [68] [69] [70] [71] . This aspect of T cell biology in RA is not fully understood. Of similar importance is the recognition that hypermetabolic cells release metabolic intermediates into their environment that are sensed by neighbouring cells, thus shaping the intensity, duration and type of inflammation present. A better understanding of such metabolic intermediates and their proinflammatory functions could broaden the potential therapeutic targets in established RA, extending beyond the successful blockade of end-stage inflammatory mediators, particularly proinflammatory cytokines such as TNF and IL-6 (REFS 72,73).
Tissue oxygen. By engulfing aerobic prokaryotes, which eventually became mitochondria, eukaryotic cells acquired the ability to utilize oxygen for energy production, and tissue oxygen levels became a major regulator of bioenergetics. First investigated in cancer cells, which have high energy needs, hypoxia-inducible factor 1α (HIF-1α) senses and connects oxygen availability to metabolic activity and ATP production, and holds a key position in both aerobic and anaerobic glycolysis 74, 75 . In tumours, HIF-1α is responsible for excessive angiogenesis, clonal selection of tumour cells and the enforcement of metabolic adaptations. Tumours often have anoxic regions and extreme hypoxic gradients throughout the tumour tissue (ranging from 0.1-6% pO 2 ) 76 . Although there does not seem to be a single hypoxic threshold that can be applied generally, oxygen levels required for hypoxia-induced gene expression are estimated to be in the range of 1-15 mmHg (REF. 77 ). The inflammatory lesion of the rheumatic joint is considered to be a hypoxic site, in which HIF-1α functions as a metabolic inducer 78, 79 . Low tissue oxygen levels are implicated in inducing mitochondrial dysfunction and in promoting a switch to glycolysis 62, 80 . Biniecka and colleagues arthroscopically measured tissue oxygen tensions in the synovium of patients with inflammatory arthritis and correlated tissue hypoxia with the induction of glycolytic activity 80 . In a group of six patients, synovial oxygen partial pressures increased from <20 mmHg to >20 mmHg upon response to treatment with TNF inhibitors, whereas a group of 13 patients who did not respond to TNF inhibitor treatment had median tissue oxygen levels of >20 mmHg before and after TNF blockade. These data indicate that the inflamed synovial lining is not as hypoxic as tumour tissues, in line with the clinical observation that in the inflamed synovium, tissue expansion outweighs tissue death. Hypoxia and excessive angiogenesis are both considered to be proinflammatory, raising the question of whether therapeutic targeting should aim to increase or reduce tissue oxygen supply 81 .
Glycolytic intermediates. The acidification of the rheumatoid joint (and other RA-associated exudates) has fascinated the scientific community for more than 50 years 82, 83 , giving rise to the idea that low glucose levels and high lactate levels could have diagnostic value. Work from the early 1970s showed higher mean oxygen uptake rates and higher mean rates of lactate appearance in saline deposited into the joints of patients with RA compared with that in the joints of patients with degenerative joint disease 84 . Studies from the past few years have confirmed the decline in glucose and the appearance of lactate in synovial fluid 85 , which are compatible with the
Box 1 | Functional consequences of metabolic reprogramming in T cells in RA
Alterations in how T cells in patients with rheumatoid arthritis (RA) utilize glucose and generate biosynthetic precursors has profound implications for intracellular signalling pathways and, eventually, differentiation into immune effector cells. Definition of the underlying molecular defects in such T cells has revealed novel therapeutic opportunities based on 'rewiring' metabolic networks.
Metabolic reprogramming of T cells in RA • CD4
+ T cells from patients with RA have markedly reduced glycolytic activity 27 , resulting in low levels of ATP and lactate • These T cells shunt glucose to the pentose phosphate pathway 28 , generating high levels of NADPH and an abundance of biosynthetic precursors • Excess NADPH leads to the accumulation of reduced glutathione and the depletion of cellular reactive oxygen species, impairing oxidation-dependent signalling pathways
Effect of metabolic constraints on cellular signalling pathways
• Defective activation of the cell cycle kinase serine-protein kinase ATM 27, 28 • Defective activation of the energy sensor AMP kinase (AMPK) 136 • Aberrant activation of mechanistic target of rapamycin complex 1 (mTORC1) 136, 137 Functional consequences of intracellular signalling abnormalities • Bypass of the G2-M cell cycle phase, leading to hyperproliferation 27, 28 • Early naive-to-memory T cell conversion 28 • Hypermigration of T cells 28, 129 • Enhanced tissue invasion by T cells 28, 129 • 
Synovial pannus
Cartilage Bone requirement of the tissue lesion to utilize glucose for fast access to energy. FLSs shift their metabolism towards anaerobic glycolysis 86 and are especially efficient in exporting lactate into the extracellular space 87 , where it acidifies the micro environment and also participates in regulating the function of surrounding cells (FIG. 4) . Local effects of lactate depend upon its concentration, as well as the ability of tissue-resident cells to sense and take up acids. Acid-sensing ion channels (cation channels activated by extracellular acid) are implicated in acid-induced cell injury, such as during chondrocyte apoptosis 88 . Tissue-resident T cells are also affected by an environment that contains lactate and might contribute actively to this environment by exporting lactate themselves 68 . When exposed to sodium lactate or lactic acid, the motility of CD4 + and CD8 + T cells is inhibited, possibly prolonging the retention of tissueinfiltrating T cells 89 . Additionally, lactate promoted IL-17 production by CD4 + T cells and induced a loss of cytolytic function in CD8 + T cells 89 . Taken together, these results suggest that the switch towards anaerobic glycolysis in synovial cells might sustain proinflammatory amplification loops and contribute directly to cellular injury (FIG. 4) . In contrast to lactate, which seems to have mainly proinflammatory functions, another intermediate of the glycolytic pathway, fructose 1,6-bisphosphate, exhibits strong anti-inflammatory properties. A single treatment with fructose 1,6-bisphosphate markedly suppressed arthritis in two animal models 90 . The protective mechanism has been linked to improved generation of ATP, which is then hydrolysed by the nucleotidases CD39 and CD73 to produce adenosine 90 . These results support the observation that the low level of ATP in T cells from patients with RA is ultimately proinflammatory 27, 28 .
Mitochondrial intermediates. Increased rates of oxygen uptake in the RA joint 84 , helped by the excessive angiogenesis known to occur at this chronically stimulated Figure 4 | Metabolic intermediates in the rheumatoid joint. The synovial pannus in the joints of patients with rheumatoid arthritis is a hypermetabolic lesion that demands high amounts of nutrients and oxygen to fulfil the energy and biosynthetic needs of its proliferative cells. The presence of glucose enables rapid and adaptive production of ATP, even under hypoxic conditions. Metabolic products such as lactate and ATP are released into the extracellular space, where they promote cell-cell communication and regulatory control. Lactate acidifies the tissue microenvironment and might directly contribute to cellular injury. With high levels of mitochondrial activity in tissue-resident and invasive cells, intermediates of the tricarboxylic acid cycle such as succinate and glutamate are secreted into the extracellular space. Signals transduced through specialized receptors (such as hydroxycarboxylic acid receptor 1 (also known as GPR81) for lactate and succinate receptor 1 (also known as GPR91) for succinate) regulate the functions of cells that sense extracellular metabolites. In this situation, metabolites serve as signalling molecules in cell-cell communication and in microenvironmental surveillance. FLS, fibroblast-like synoviocyte.
Warburg effect
The high utilization of glycolysis by rapidly proliferating cells and the subsequent release of lactate into the extracellular milieu; a phenomenon first desribed by Otto Warburg.
tissue site 91, 92 , indicate that mitochondrial metabolism remains intact and contributes to ATP generation. Mitochondria not only consume oxygen to generate ATP, but also produce metabolic intermediates of the TCA cycle that participate in a multitude of metabolic pathways 93 . The concentrations of several of these TCA cycle intermediates, including succinate, citrate, glutamate, fumarate and aspartate, are altered in continuously proliferating cancer cells 94 . The same mitochondrial intermediates are also enriched in synovial fluid 95 and, like lactate, have functions beyond their role as anabolic metabolites [96] [97] [98] . The presence of such TCA cycle intermediates in synovial fluid suggests that the synovial pannus represents an oxygenated environment with ample access to sources of carbohydrates, amino acids and lipids.
Several TCA cycle intermediates have been identified as potential amplifiers of inflammatory activity and as possible therapeutic targets [99] [100] [101] [102] (FIG. 4) . Glutamate concentrations are elevated in arthritic joints; the triggering of glutamate receptors increases the release of IL-6 and induces arthritic pain 103 . Synovial fluid from patients with RA also contains an abundance of succinate, a product released into the extracellular milieu by activated macrophages. Interestingly, such macrophages express succinate receptor 1 (also known as GPR91), through which they sense succinate levels and induce inflammasome activation 104 . Previously, succinate has been demonstrated to modulate dendritic cell function by triggering succinate receptor 1 (REF. 105 ) and to induce IL-1β production in lipopolysaccharide-treated macrophages by stabilizing HIF-1α 106 . Another important product of the mitochondria of activated tissue macrophages is ROS, which remodel inflammatory signalling networks and sustain IL-1β and IL-6 production by enhancing the phosphorylation of signal transducer and activator of transcription 3 (REF. 107 ).
Alarmins. Cells under stress actively or passively release endogenous danger signals (known as alarmins), including high mobility group protein B1 (HMGB1), S100A proteins, heat shock proteins and purine metabolites (such as uric acid and ATP). Innate and adaptive immune cells sense such extracellular alarmins through specific receptors, which trigger and fine-tune inflammatory and repair responses 108, 109 . ATP, produced by glycolysis or oxidative phosphorylation in the mitochondria, is exported into the extracellular space, where it has been associated with anti-inflammatory activity (FIG. 4) . Lymphocytes from patients with RA have high levels of CD39 activity, which could lead to insufficient preservation of extracellular ATP 110 . Conversely, ATPdependent activation of the P2X7 purine receptor on mast cells upregulates protein arginine deiminase 111 , an enzyme involved in the conversion of arginine residues into citrulline, a post-translational modification considered to be arthritogenic in RA. P2X7 is found on human FLSs 112 , enabling these cells to closely monitor ATP levels in the extracellular milieu. In general, by monitoring ATP levels cells can closely assess the metabolic activity and the metabolic pathways preferred by their neighbouring cells. Expression of CD39 on T cells seems to be particularly important for memory cells and is a marker of T cell ageing 113 . DNA, of both nuclear and mitochondrial origin, can acquire alarmin function when released into the extracellular space, where nucleic acids can engage patternrecognition receptors on surrounding cells 114 . This mechanism could enable the communication of metabolic stress, as synovial cells sense not only mitochondrial intermediates but also mitochondrial DNA 115 .
Other inflammatory networks. A number of inflammatory processes that are ultimately dependent on energy supply and the metabolic environment contribute to the pathogenesis of RA, as permissive factors and as aggravators of tissue injury. Abnormalities in autophagy are suspected to determine cellular hyperplasia as well as cell loss 116 . PFKFB3, the glycolytic enzyme implicated in metabolic reprogramming of T cells in the early stages of RA 31 , is also linked to the control of autophagy 32 . The identification of genetic mutations in inflammasome activation pathways in patients with auto inflammatory syndromes has also been instructive in connecting molecular networks to inflammatory outcomes, and has highlighted the multiple roles of mitochondria in regulating inflammation 117, 118 .
Metabolomics in RA
Progress in technologies such as mass spectrometry and chromatography that enable increased precision of mass detection and metabolite identification have driven interest in the measurement of hundreds of metabolites in cells, tissues and fluids. In patients with RA, plasma, serum, synovial fluid and synovial tissue have all been utilized for metabolomics studies [119] [120] [121] [122] . No unifying metabolic marker(s) has been discovered, but some common signatures have emerged. Using metabo lomics, patients can be differentiated from healthy controls, anti-inflammatory treatments can be seen to affect metabolite patterns, and patients in therapy-induced remission can still be distinguished from healthy individuals [119] [120] [121] [122] (which shows that current therapies improve but do not cure underlying pathologies). Importantly, these studies show that inflammation in patients with RA is a complex process, extending far beyond lactate production. Although less efficient than oxidative phosphorylation, the evolutionarily ancient process of anaerobic glycolysis can be upregulated within minutes. Metabolomics studies in patients with RA have revealed that a switch to aerobic glycolysis, the so-called Warburg effect, is not enough to capture all metabolic adaptations associated with the disease process. In a 2010 study by Lauridsen et al. 123 , increased amounts of cholesterol and unsaturated lipids and a decreased amount of HDL cholesterol distinguished patients with RA from healthy individuals. Decreased lipid signals were also the major discriminators between patients with RA and healthy individuals in a 2013 study by Young et al. 124 . These authors also identified high levels of 3-hydroxy butyrate as a marker for RA, suggesting increased lipolytic activity 124 .
A 2016 study highlighted increased levels of fatty acids and cholesterol and decreased levels of amino acids and glucose in patients with RA 125 . Another signature reported for metabolites in the blood of patients with RA includes low levels of valine, isoleucine, alanine, creatinine, histidine and lactate and high levels of 3-hydroxyisobutyrate, acetate, N-acetylcysteine, acetoacetate and acetone 126 . Fatigue in patients with RA is associated with downregulation of metabolites from the urea cycle (such as fatty acids, tocopherols, aromatic amino acids and hypoxanthine) 127 .
Collectively, metabolomics studies provide many opportunities both clinically and conceptually, yet the data from these studies have not yet been used to their full effect. Part of the problem lies in the heterogeneity of cells and tissues that actively or passively release metabolites that accumulate in body fluids. The functional effects of such metabolites are dictated by their abundance in tissue microenvironments, the activity of transport mechanisms and the diversity of cell types that generate and use them. Increased levels of a metabolite might indicate a lack of utilization or compensatory production, whereas decreased levels might result from disproportionate utilization or insufficient generation. To define evidence-based pathways for potential clinical translation, researchers will need to use functional metabolomics studies to evaluate how defined metabolic products affect cellular and multi-cellular homeostasis.
An obvious question is whether the analysis of metabolites in the inflammatory environment, as captured in synovial fluid or tissue, yields novel insights into the nature of the inflammation. An abundance of succinate, aspartate, glutamate and citrulline in synovial fluid from patients with RA attests to the intense levels of mitochondrial metabolic activity 95 . Conversely, levels of isopalmitic acid, glycerol, myristic acid, palmitoleic acid, hydroxylamine and ethanolamine are low in patients with RA 100, 104 .
Conclusions
As a prototypic autoimmune disease, RA begins with the immune system making a fundamental mistake -not being able to distinguish self from non-selfwith the end result of relentless inflammation in the synovial microenvironment. Although the location, intensity and specific pathways of disease vary over the lifetime of the patient, tolerance breakdown, subclinical RA and clinical RA share the need for cellular expansion and biomass generation. How cells fulfil the consequent demands for cellular energy and biosynthetic precursors has emerged as a critical domain in autoimmune inflammation.
The early stages of RA, in which T cells break the state of tolerance and provide help to autoantibody-producing B cells, unfold in lymphoid tissues and involve cells that have not yet made a lineage commitment. Metabolically, naive T cells from patients with RA are dysregulated and respond to activation by shunting glucose into the PPP. Such T cells generate low levels of ATP and lactate, but have excess NADPH and biosynthetic precursors.
Consequently, these T cells have reduced levels of intracellular ROS, impaired redox signalling and insufficiently activate the cell cycle kinase ATM. The result is a hyperproliferative T cell that is biased towards T H 1 and T H 17 effector cell functions. Although the underlying defects that lead to metabolic reprogramming are not fully understood, divergence of glucose utilization towards synthetic and proliferative functions is now recognized as part of the DNA repair and T cell ageing programme 128 . Premature ageing in T cells from patients with RA is connected to telomere instability. Reduced activity of the DNA repair nuclease MRE11A induces a cellular senescence module that is defined by gain of the cell cycle regulators p16 and p21 and the cell surface receptor CD57 (REF 129) . Shunting glucose towards the PPP and telomeric uncapping are both directly implicated in the tissue invasive and proinflammatory properties of T cells from patients with RA, indicating shared upstream abnormalities 27, 129 . The metabolic environment of the inflamed joint is demonstrably altered, in line with the high metabolic activity of chronically active lymphoid and stromal cells. Proliferating stromal cells use glucose as an energy source and acidify the tissue microenvironment by releasing lactate. Excess TCA cycle intermediates suggest high levels of mitochondrial activity, possibly fuelled by angiogenesis delivering oxygen to the tissue. Extracellular glutamate and succinate have been linked to proinflammatory functions, exemplifying the increasingly recognized role of such metabolites as signalling molecules, above and beyond their anabolic contributions 130, 131 . An obvious motivation to better understand the metabolism of inflammatory immune cells is the idea that tailored exercise programmes, dietary habits and selected nutrients might be applied in the management of RA. Omega-3 fatty acids, moderate alcohol consumption and strict adherence to a Mediterranean diet reportedly have beneficial effects on RA disease activity 132 , supporting the notion that dietary interventions could be developed as additional immunomodulatory treatments for patients with RA. Molecular studies and well-designed clinical trials will help with the design of disease-specific recommendations. Conversely, clarifying how immunosuppressive drugs that successfully treat RA, such as methotrexate, chloroquine and TNF inhibitors, interfere with metabolic processes could provide useful clues as to how metabolism is connected to RA and its comorbidities 133 . Evolving therapeutic strategies that exploit metabolic regulation as a therapeutic target in rheumatic diseases are reviewed in another article in this journal 134 . Analysis of the metabolic pathways in RA widens the pathogenic concept of this disease beyond a narrow view of autoimmunity triggered by the recognition of an autoantigen. An increased knowledge of metabolism promises to yield insights into the relationship between genes and environment in the decades-long disease process, to enable an integrated view of hostmicrobiota interactions and to invigorate the discussion of nutraceuticals as novel therapeutic agents 135 .
